Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess whether treatment with a single oral 300 mg dose of
canagliflozin alters the kinetics (ie, clearance/removal from body) of serum C-peptide (a
protein released from the pancreas during insulin secretion) in healthy adult volunteers.